1. Home
  2. RBOT vs ACOG Comparison

RBOT vs ACOG Comparison

Compare RBOT & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vicarious Surgical Inc.

RBOT

Vicarious Surgical Inc.

HOLD

Current Price

$3.05

Market Cap

17.0M

Sector

Health Care

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$6.50

Market Cap

130.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBOT
ACOG
Founded
2014
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.0M
130.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RBOT
ACOG
Price
$3.05
$6.50
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$7.00
$18.00
AVG Volume (30 Days)
152.1K
89.3K
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,427,199.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$143.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.44
$3.75
52 Week High
$19.00
$11.54

Technical Indicators

Market Signals
Indicator
RBOT
ACOG
Relative Strength Index (RSI) 39.85 56.55
Support Level $2.54 $5.66
Resistance Level $3.66 $6.18
Average True Range (ATR) 0.38 0.42
MACD 0.11 0.10
Stochastic Oscillator 44.26 90.29

Price Performance

Historical Comparison
RBOT
ACOG

About RBOT Vicarious Surgical Inc.

Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: